Product Details
Place of Origin: China
Brand Name: Sunshine
Certification: COA,ISO
Model Number: 910463-68-2
Payment & Shipping Terms
Minimum Order Quantity: Negotiation
Price: Negotiation
Packaging Details: Aluminum Foil Bag, Drum
Delivery Time: 7-15 working days
Payment Terms: T/T,L/C,D/A,Western Union
Supply Ability: 1Ton/Month
CAS NO:: |
910463-68-2 |
Appearance：: |
White Powder |
Molecular Formula:: |
C187H291N45O59 |
Molecular Weight:: |
4113.580 |
EINECS NO:: |
691-729-9 |
MDL NO:: |
NA |
CAS NO:: |
910463-68-2 |
Appearance：: |
White Powder |
Molecular Formula:: |
C187H291N45O59 |
Molecular Weight:: |
4113.580 |
EINECS NO:: |
691-729-9 |
MDL NO:: |
NA |
We can provide GMP/DMF file support for this product, as well as other different standards to meet your specific requirements.
| CAS NO. | Chemical name |
|---|---|
| 910463-68-2 | GLP-1 analogue |
| 1662688-20-1 | Fmoc-L-Lys[Oct-(otBu)-Glu-(otBu)-AEEA-AEEA]-OH |
| 1446013-07-5 | Fmoc-His-Aib-OH |
| 1169630-40-3 | Ste-Glu-AEEA-AEEA-OSU |
| 1118767-16-0 | tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu |
| 1169630-82-3 | Semaglutide intermediate P29 |
| 203787-91-1 | Salcaprozate Sodium |
This product is a long-acting dosage form developed based on the basic structure of liraglutide, demonstrating enhanced efficacy in the treatment of type 2 diabetes. As a new generation GLP-1 (glucagon-like peptide-1) analogue developed by Novo Nordisk, Denmark, it represents an advancement in diabetes treatment options.
Novo Nordisk has completed six Phase IIIa studies and submitted a new drug registration application to the U.S. Food and Drug Administration (FDA) on December 5, 2016 for weekly administration of somalutide. A marketing authorisation application (MAA) has also been submitted to the European Medicines Agency (EMA). Somalutide is currently in Phase III clinical trials for a once-daily oral formulation.
